GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (NAS:EVGN) » Definitions » Cyclically Adjusted PS Ratio

EVGN (Evogene) Cyclically Adjusted PS Ratio : 0.78 (As of May. 29, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Evogene Cyclically Adjusted PS Ratio?

As of today (2025-05-29), Evogene's current share price is $1.0995. Evogene's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $1.41. Evogene's Cyclically Adjusted PS Ratio for today is 0.78.

The historical rank and industry rank for Evogene's Cyclically Adjusted PS Ratio or its related term are showing as below:

EVGN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.7   Med: 2.35   Max: 5.05
Current: 0.79

During the past years, Evogene's highest Cyclically Adjusted PS Ratio was 5.05. The lowest was 0.70. And the median was 2.35.

EVGN's Cyclically Adjusted PS Ratio is ranked better than
86.12% of 497 companies
in the Biotechnology industry
Industry Median: 5.33 vs EVGN: 0.79

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Evogene's adjusted revenue per share data for the three months ended in Mar. 2025 was $0.360. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.41 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Evogene Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Evogene's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evogene Cyclically Adjusted PS Ratio Chart

Evogene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.02 3.92 1.28

Evogene Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 3.61 1.73 1.28 0.89

Competitive Comparison of Evogene's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Evogene's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evogene's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evogene's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evogene's Cyclically Adjusted PS Ratio falls into.


;
;

Evogene Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Evogene's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.0995/1.41
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evogene's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Evogene's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.36/134.9266*134.9266
=0.360

Current CPI (Mar. 2025) = 134.9266.

Evogene Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 1.073 100.684 1.438
201509 1.272 100.392 1.710
201512 0.988 99.792 1.336
201603 0.777 100.470 1.043
201606 0.729 101.688 0.967
201609 0.601 101.861 0.796
201612 0.461 101.863 0.611
201703 0.283 102.862 0.371
201706 0.459 103.349 0.599
201709 0.290 104.136 0.376
201712 0.285 104.011 0.370
201803 0.142 105.290 0.182
201806 0.147 106.317 0.187
201809 0.143 106.507 0.181
201812 0.247 105.998 0.314
201903 0.135 107.251 0.170
201906 0.075 108.070 0.094
201909 0.038 108.329 0.047
201912 0.045 108.420 0.056
202003 0.029 108.902 0.036
202006 0.116 108.767 0.144
202009 0.117 109.815 0.144
202012 0.103 109.897 0.126
202103 0.085 111.754 0.103
202106 0.033 114.631 0.039
202109 0.037 115.734 0.043
202112 0.076 117.630 0.087
202203 0.058 121.301 0.065
202206 0.076 125.017 0.082
202209 0.113 125.227 0.122
202212 0.157 125.222 0.169
202303 0.154 127.348 0.163
202306 0.156 128.729 0.164
202309 0.767 129.860 0.797
202312 0.114 129.419 0.119
202403 0.824 131.776 0.844
202406 0.180 132.554 0.183
202409 0.309 133.029 0.313
202412 0.237 133.157 0.240
202503 0.360 134.927 0.360

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evogene  (NAS:EVGN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Evogene Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Evogene's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evogene Business Description

Industry
Traded in Other Exchanges
Address
13 Gad Feinstein Street, Park Rehovot, Ness Ziona, Rehovot, ISR, 7638517
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.